Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond
You may also be interested in...
Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says
TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa
Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says
TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa
South Korea’s BiocurePharm To Produce Biosimilars In Thailand
SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13